EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Claire N Harrison iD, Jyoti Nangalia iD, Rebecca Boucher iD, Aimee Jackson, Christina Yap iD, Jennifer O'Sullivan, Sonia Fox, Isaak Ailts iD, Amylou C Dueck iD, Holly L Geyer, Ruben A Mesa iD, William G Dunn iD und 21 weitere

Journal of Clinical Oncology · 01.07.2023 · 41 (19) · 3534-3544

DOI: 10.1200/jco.22.01935 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.07.2023. Verfasst von Claire N Harrison und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. Hauptthemen laut MEDLINE: Polycythemia Vera. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms. PATIENTS AND METHODS MAJIC-PV is a randomized phase II trial of ruxolitinib versus best available therapy (BAT) in patients resistant/intolerant to hydroxycarbamide (HC-INT/RES). Primary outcome was complete response (CR) within 1 year. Secondary outcomes included duration of response, event-free survival (EFS), symptom, and molecular response. RESULTS One hundred eighty patients were randomly assigned. CR was achieved in 40 (43%) patients on ruxolitinib versus 23 (26%) on BAT (odds ratio, 2.12; 90% CI, 1.25 to 3.60; P = .02). Duration of CR was superior for ruxolitinib (hazard ratio [HR], 0.38; 95% CI, 0.24 to 0.61; P < .001). Symptom responses were better with ruxolitinib and durable. EFS (major thrombosis, hemorrhage, transformation, and death) was superior for patients attaining CR within 1 year (HR, 0.41; 95% CI, 0.21 to 0.78; P = .01); and those on ruxolitinib (HR, 0.58; 95% CI, 0.35 to 0.94; P = .03). Serial analysis of JAK2V617F variant allele fraction revealed molecular response was more frequent with ruxolitinib and was associated with improved outcomes (progression-free survival [PFS] P = .001, EFS P = .001, overall survival P = .01) and clearance of JAK2V617F stem/progenitor cells. ASXL1 mutations predicted for adverse EFS (HR, 3.02; 95% CI, 1.47 to 6.17; P = .003). The safety profile of ruxolitinib was as previously reported. CONCLUSION The MAJIC-PV study demonstrates ruxolitinib treatment benefits HC-INT/RES PV patients with superior CR, and EFS as well as molecular response; importantly also demonstrating for the first time, to our knowledge, that molecular response is linked to EFS, PFS, and OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycythemia VeraHumansTreatment OutcomeHydroxyureaNitrilesHemorrhagePyrazolesPyrimidines

Substanzen

HydroxyureaNitrilesruxolitinibPyrazolesPyrimidines

Autor:innen und Institutionen

  • Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
  • Wellcome Sanger Institute Hinxton, Cambridgeshire, United Kingdom.
  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Clinical Trials and Statistics Unit, The Institute of Cancer Research, United Kingdom.

ORCID-Profile: Claire N Harrison, Jyoti Nangalia, Rebecca Boucher, Christina Yap, Isaak Ailts, Amylou C Dueck, Ruben A Mesa, William G Dunn, Mamta Garg, Steven Knapper, Josephine Crowe, Ioannis Koutsavlis, Siamak Arami, Jennifer Byrne, Elizabeth Joanna Baxter, Mary Frances McMullin, Adam J Mead

Förderung

  • Medical Research Council
  • Cancer Research UK

Zitieren

APA

Harrison, C. N., Nangalia, J., Boucher, R., Jackson, A., Yap, C., O'Sullivan, J., Fox, S., Ailts, I., Dueck, A. C., Geyer, H. L., Mesa, R. A., Dunn, W. G., Nadezhdin, E., Curto-Garcia, N., Green, A., Wilkins, B., Coppell, J., Laurie, J., Garg, M., …, & Mead, A. J. (2023). Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. Journal of Clinical Oncology, 41(19), 3534-3544. https://doi.org/10.1200/jco.22.01935

Vancouver

Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O'Sullivan J, et al. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. Journal of Clinical Oncology. 2023;41(19):3534-3544. doi:10.1200/jco.22.01935

BibTeX
@article{Harrison2023,
  author = {Harrison, Claire N and Nangalia, Jyoti and Boucher, Rebecca and Jackson, Aimee and Yap, Christina and O'Sullivan, Jennifer and Fox, Sonia and Ailts, Isaak and Dueck, Amylou C and Geyer, Holly L and Mesa, Ruben A and Dunn, William G and Nadezhdin, Eugene and Curto-Garcia, Natalia and Green, Anna and Wilkins, Bridget and Coppell, Jason and Laurie, John and Garg, Mamta and Ewing, Joanne and Knapper, Steven and Crowe, Josephine and Chen, Frederick and Koutsavlis, Ioannis and Godfrey, Anna and Arami, Siamak and Drummond, Mark and Byrne, Jennifer and Clark, Fiona and Mead-Harvey, Carolyn and Baxter, Elizabeth Joanna and McMullin, Mary Frances and Mead, Adam J},
  title = {Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {19},
  pages = {3534--3544},
  doi = {10.1200/jco.22.01935}
}
Kostenlos starten →